Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going | Zendy

Luis Gabriel ParraLara | Zendy; Juan José Martínez | Zendy; Fernando Rosso | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going

Author(s) -

Luis Gabriel ParraLara,

Juan José Martínez,

Fernando Rosso

Publication year - 2020

Publication title -

journal of global antimicrobial resistance

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.917

H-Index - 26

eISSN - 2213-7173

pISSN - 2213-7165

DOI - 10.1016/j.jgar.2020.06.016

Subject(s) - azithromycin , hydroxychloroquine , medicine , covid-19 , intensive care medicine , clinical trial , adverse effect , virology , pharmacology , antibiotics , outbreak , microbiology and biotechnology , disease , infectious disease (medical specialty) , biology

Highlights • Azithromycin (AZM) is a promising drug candidate for the treatment of the COVID-19.• Studies so far on the use of AZM in COVID-19 patients have various methodological limitations.• The evidence on the efficacy of AZM as an adjunct to hydroxychloroquine for COVID-19 is not enough yet.• Combination of AZM and HCQ should be decided with caution due serious cardiac adverse effects.• Currently, 21 clinical trials are being carried out on the use of AZM in COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research